What You Will Learn

Please join Carterra and WuXi Biologics at our upcoming symposium in Oxford, United Kingdom. You will spend the day learning about high-throughput drug discovery with some of the industry’s leading scientists. Our speakers will present new ways of looking at discovery, applications, and workflows, including HT-SPR. The topics you'll hear about include:

Workflows enhancing the speed or efficiency of drug discovery
AI and ML initiatives and in silico antibody discovery programs
Small molecule applications: TPDs, DELs, PROTAC^®s, Membrane Proteins
Novel assay designs including HT-SPR applications
Emerging modalities such as next-gen antibodies: scFVs, nanobodies, bi-specifics, ADCs
Strategies to maximize impact in specific therapeutic areas such as immuno-oncology, infectious diseases, and neuroscience

Network with your peers. Lunch will be provided. Registration is required as seating is limited.

Companies presenting in 2024:

Agenda	Symposium co-hosted by WuXi Biologics
9:45 – 10:00	Arrive and Check-in
10:00 – 10:30	Networking and Coffee/Tea
10:30 – 10:45	Symposium Begins—Welcome
10:45 – 11:15	Kirsty McHugh, PhD, Senior Postdoctoral Scientist, University of Oxford High-throughput isolation and characterisation of monoclonal antibodies against PfRH5 – the leading blood-stage malaria vaccine candidate
	Abstract: Plasmodium falciparum malaria is a major cause of morbidity and mortality, and new interventions are urgently needed. The P. falciparum reticulocyte-binding protein homolog 5 (PfRH5) antigen is a leading blood-stage vaccine candidate. Vaccines targeting PfRH5 have demonstrated antibody-mediated efficacy in clinical trials, but high, durable titers of inhibitory antibodies must be induced, a challenge which is difficult to meet with current generation vaccines. Our group have generated a broad panel of over 200 anti-PfRH5 monoclonal antibodies from PfRH5-vaccinated UK adult volunteers. By combining high throughput epitope binning using the Carterra LSA^® platform with in vitro parasite growth inhibition assays we have revealed the diverse antigenic landscape of PfRH5 and identified inhibitory epitopes to a fine resolution. These results will help inform our next-generation vaccine design.
11:15 – 11:45	Jiansheng Wu, PhD, VP, Head of Protein Sciences, WuXi Biologics Unlocking the Optimal Pairings of Bispecific Antibodies & Efficient Scale-Up Strategies
	Abstract: With increasing interest in bispecific antibodies (bsAbs) for therapeutic development and AI integration in drug discovery, the demand for high throughput (HTP) bsAb production has soared. However, bsAb production faces challenges such as heterogeneity, production complexity, and stability issues, which impact the quality of the final product. This presentation will reveal innovative strategies to address these challenges, from small-scale HTP production of a vast number of bispecific antibody pairings to efficient scale-up after identifying optimal pairings. Real-world case studies will demonstrate the successful application of these strategies, achieving high yield and purity (>99% heterodimers) of bsAbs.
11:45 – 12:15	Xavier Pierrat, PhD, Senior Investigator, Ichnos Sciences Implementation of high-throughput SPR measurements to streamline IGI antibody discovery platform
	Abstract: The complexity in designing potent multispecific immune engagers to treat cancer is multi-factorial and relies on advanced screening capabilities to select the optimal molecules. The Ichnos-Glenmark-Innovation (IGI) discovery engine includes common light chain (cLC) Fab discovery by phage and mammalian display, and screening for optimal affinity, epitope, developability and architecture. To streamline this process, we have recently implemented the LSA instrument enabling high affinity measurement, epitope binning and early developability assessment.
12:15 – 13:30	Lunch and Networking
13:30 – 14:00	Jon Popplewell, PhD, Field Application Scientist , Carterra Driving discovery of novel medicines using Carterra’s HT-SPR technology
	Abstract: Carterra’s LSA^® and LSA^XT platforms have changed the landscape of drug discovery. Across small and large molecule therapies as well as vaccines, the power of high throughput multiplexing and innovative assay configurations is enabling new strategies to tackle the undruggable space and discover novel medicines. This talk will emphasize areas where HT-SPR technology continues to push the boundaries of real-time, label-free binding. With HT-SPR, research workflows benefit from seamless data integrations and the necessary breadth and depth of data to deliver on the promises of AI/ML-based drug discovery.
14:00 – 14:30	Ciarra McGoran, MSc, Associate Scientist, GSK Refining the use of the Carterra LSA^® for high throughput screens in antibody discovery
	Abstract: The Carterra LSA has provided us with the scope to generate affinities for hundreds of antibodies against several targets. However, when focusing on increasing throughput it is important to ensure that data quality is maintained. Since the introduction of the LSA to our labs, we have been developing new ways to obtain, analyse and store data. I will be discussing the optimisation of immobilisation methods to generate capture surfaces. In addition, I will discuss the impact this has had on our ability to characterise high affinity interactions, and on our confidence in our high throughput screening data.
14:30 – 15:00	Networking and Refreshments
15:00	Symposium Ends

What You Will Learn

Register Here

Agenda